Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FP253 + fludarabine
- Development stage
- Unknown
- Lead developer
- Foreland Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
FP253 + fludarabine is an investigational drug combination being studied for cancer therapy. FP253 (also known as FP-253) is a small molecule agonist of sphingosine 1-phosphate receptors (S1PRs), developed by Foreland Pharma. Its mechanism involves S1PR activation, which may modulate immune cell trafficking and other cellular processes relevant to oncology. Fludarabine is a purine analog antimetabolite used primarily in the treatment of B-cell chronic lymphocytic leukemia (CLL). It inhibits DNA polymerase alpha, ribonucleotide reductase, and DNA primase—thereby blocking DNA synthesis and leading to cancer cell death[1][2][3][8]. The combination has been investigated in early-phase clinical trials for prostate cancer[4].
- Other names
- fludarabine phosphate2-fluoro-ara-A2-fluoro-ara-ATP
02
Targets
POLA1 (DNA polymerase alpha)KCNA3 (Potassium voltage-gated channel subfamily A member 3)EDG1 (Sphingosine-1-phosphate receptors)RNR (Ribonucleotide reductase)DNA-directed primase/polymerase protein (PrimPol)
Beyond the preview
Go deeper on FP253 + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FP253 + fludarabine.